XTX Topco Ltd Acquires 26,073 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• XTX Topco Ltd increased its stake in Hims & Hers Health, acquiring an additional 26,073 shares and bringing its total holdings to 50,909 shares, valued at approximately $1.5 million.
• Institutional investors collectively own 63.52% of Hims & Hers Health, indicating strong interest from large financial entities.
• Despite recent growth, Wall Street analysts have mixed opinions, with reports indicating a consensus target price of $39.83 and multiple hold and sell ratings issued.

XTX Topco Ltd grew its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 105.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,909 shares of the company's stock after acquiring an additional 26,073 shares during the period. XTX Topco Ltd's holdings in Hims & Hers Health were worth $1,504,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. N.E.W. Advisory Services LLC purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $49,000. Meeder Asset Management Inc. grew its stake in Hims & Hers Health by 49,043.1% during the 1st quarter. Meeder Asset Management Inc. now owns 35,383 shares of the company's stock valued at $1,046,000 after acquiring an additional 35,311 shares in the last quarter. LPL Financial LLC grew its stake in Hims & Hers Health by 0.8% during the 1st quarter. LPL Financial LLC now owns 98,701 shares of the company's stock valued at $2,917,000 after acquiring an additional 743 shares in the last quarter. CloudAlpha Capital Management Limited Hong Kong purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $20,580,000. Finally, Navellier & Associates Inc. purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $219,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $47.70, for a total transaction of $552,413.70. Following the completion of the transaction, the chief financial officer owned 54,084 shares of the company's stock, valued at $2,579,806.80. This represents a 17.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 2,100 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total value of $120,792.00. Following the completion of the sale, the insider directly owned 278,654 shares of the company's stock, valued at approximately $16,028,178.08. The trade was a 0.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 737,704 shares of company stock worth $40,644,035. Corporate insiders own 13.71% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Bank of America increased their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday, April 29th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial increased their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research report on Thursday, July 17th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Price Performance

Shares of HIMS stock traded down $3.61 during trading hours on Friday, reaching $62.57. The stock had a trading volume of 26,677,206 shares, compared to its average volume of 30,852,940. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The firm has a 50-day simple moving average of $53.62 and a 200-day simple moving average of $44.04. The firm has a market capitalization of $14.01 billion, a PE ratio of 90.68, a price-to-earnings-growth ratio of 2.44 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the previous year, the company posted $0.05 EPS. The business's revenue was up 110.7% compared to the same quarter last year. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.